Cancer News and Research

Latest Cancer News and Research

Alpha-herpesvirus axon-to-cell spread involves limited virion transmission

New research suggests that just one or two individual herpes virus particles attack a skin cell in the first stage of an outbreak, resulting in a bottleneck in which the infection may be vulnerable to medical treatment.

7 Nov 2012

Laws that end smoking result in fewer hospitalizations for heart attacks, strokes

Laws that end smoking at work and other public places result in significantly fewer hospitalizations for heart attacks, strokes, asthma and other respiratory conditions, a new UCSF analysis has found.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

MASP-1 enzyme plays a central role in activating the complement system

Researchers from Aarhus University, Denmark, have now discovered an important mechanism behind one of our most fundamental lines of immune function. The discovery has been published in the esteemed scientific journal, The Journal of Immunology, where it has been highlighted as a top story.

7 Nov 2012

Measuring blood levels of hs-CRP could help identify men at increased risk for death from cancer

Measuring blood levels of high-sensitive C-reactive protein, an important marker of inflammation, in apparently cancer-free men could potentially help identify those at increased risk for death from cancer, in particular lung cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Nov 2012

EPO provides notice of intent to issue European Patent Application for Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the European Patent Office (EPO) has provided the Company a notice of intent to issue European Patent Application No. 04 703 672.8 entitled "Method For Removal of Viruses From Blood By Lectin Affinity Hemodialysis."

7 Nov 2012

Low vitamin D levels mediate racial disparities in pain

A new study reveals that black Americans display lower levels of vitamin D and greater pain sensitivity compared to white Americans. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), indicate that vitamin D deficiency may be one of many factors that account for increased pain in older black Americans with knee osteoarthritis (OA).

7 Nov 2012

UCLA study to uncover risk profiles of breast cancer survivors likely to suffer from depression

UCLA researchers received a five-year, $5 million grant from the National Cancer Institute that will fund a study seeking to uncover risk profiles of breast cancer survivors likely to suffer from depression.

7 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.

7 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Geldanamycin degrades VEGFR2 protein that triggers blood vessel growth

The drug, geldanamycin, is well known for attacking a protein associated with the spread of breast cancer. However, a laboratory-based study found it also degraded a different protein that triggers blood vessel growth.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Viewpoints: Fight for the Senate will impact GOP effort to void health law; Figuring out insurance is tough even for health economist

For Republicans intent on unraveling President Obama's accomplishments, electing Mitt Romney has been only one part of the equation. Almost as important was installing a Republican majority in the United States Senate, where 50 votes (plus the vice president) would be necessary to repeal much of health care reform, roll back tax increases on the rich and gut social welfare programs. The party's hopes, however, have been severely damaged in recent weeks.

6 Nov 2012

Biologists determine how blind mole rats fight off cancer

Biologists at the University of Rochester have determined how blind mole rats fight off cancer-and the mechanism differs from what they discovered three years ago in another long-lived and cancer-resistant mole rat species, the naked mole rat.

6 Nov 2012

More calories consumed when eating out

Children and adolescents consume more calories and soda and have poorer nutrient-intake on days they eat at either fast-food or full-service restaurants, as compared to days they eat meals at -- or from -- home.

6 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Doctors step up fight for cancer prevention, treatment in developing world

"Doctors were at the forefront of the AIDS treatment revolution a decade ago, denouncing stigmatization and inequality from conference platforms and lobbying politicians alongside the activists," Guardian health editor Sarah Boseley writes in her "Global Health" blog.

6 Nov 2012

Patients with diabetes, multi-vessel coronary artery disease can benefit from bypass surgery

An international, clinical research trial has shown that patients with diabetes whose multi-vessel coronary artery disease is treated with bypass surgery live longer and are less likely to suffer severe complications like heart attacks than those who undergo angioplasty.

6 Nov 2012

Celldex to present results from CDX-301 Phase 1 study in healthy volunteers

Celldex Therapeutics, Inc. today announced an upcoming data presentation at the American Society of Hematology 54th Annual Meeting and Exposition to be held in Atlanta, GA from December 8 through December 11, 2012.

6 Nov 2012